The SUMO protease SENP1 and the chromatin remodeler CHD3 interact and jointly affect chromatin accessibility and gene expression

Received for publication, March 12, 2018, and in revised form, July 12, 2018. Published, Papers in Press, August 6, 2018, DOI 10.1074/jbc.A118.002844

Fernando Rodríguez-Castañeda‡1, Roza Berhanu Lemma1, Ignacio Cuervo5‡, Mads Bengtsen4, Lisa Marie Moen1, Marit Ledsaak1, Ragnhild Eskeland45, and Odd Stokke Gabrielsen12

From the 4Department of Biosciences, University of Oslo, P. O. Box 1066 Blindern, N-0316 Oslo and the 6Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, University of Oslo, P.O. Box 1112 Blindern, N-0317 Oslo, Norway

Edited by Joel Gottesfeld

The small ubiquitin-like modifier (SUMO) post-translationally modifies lysine residues of transcription factors and co-regulators and thereby contributes to an important layer of control of the activities of these transcriptional regulators. Likewise, deSUMOylation of these factors by the sentrin-specific proteases (SENP s) also plays a role in gene regulation, but whether SENPs functionally interact with other regulatory factors that control gene expression is unclear. In the present work, we focused on SENP1, specifically, on its role in activation of gene expression investigated through analysis of the SENP1 interactome, which revealed that SENP1 physically interacts with the chromatin remodeler chromodomain helicase DNA-binding protein 3 (CHD3). Using several additional methods, including GST pulldown and co-immunoprecipitation assays, we validated and mapped this interaction, and using CRISPR-Cas9–generated CHD3- and SENP1-KO cells (in the haploid HAP1 cell line), we investigated whether these two proteins are functionally linked in regulating chromatin remodeling and gene expression. Genome-wide ATAC-Seq analysis of the CHD3- and SENP1-KO cells revealed a large degree of overlap in differential chromatin openness between these two mutant cell lines. Moreover, motif analysis and comparison with ChIP-Seq profiles in K562 cells pointed to an association of CHD3 and SENP1 with CCCTC-binding factor (CTCF) and SUMOylated chromatin–associated factors. Lastly, genome-wide RNA-Seq also indicated that these two proteins co-regulate the expression of several genes. We propose that the functional interaction between chromatin remodeling by CHD3 and deSUMOylation by SENP1 uncovered here provides another level of control of gene expression.

This work was supported by Norwegian Cancer Society Grant 3485238-2013 (to R.E.) and Research Council of Norway Grants 240768 (to O.S.G.) and 231217 (to R.E.). The authors declare that they have no conflicts of interest with the contents of this article.

This article was selected as one of our Editors’ Picks. This article contains Figs. S1–S13, supporting Materials and Methods, and supporting Refs. 1–19.

The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession numbers GSE111272 and GSE111047.

‡ Both authors contributed equally to this work.

1 To whom correspondence should be addressed. Tel.: 47-22-85-73-46 (office) and 47-415-60-130 (mobile); E-mail: o.s.gabrielsen@ibv.uio.no.

SUMOylation is a fundamental post-translational modification (PTM) involved in a broad range of cellular processes such as transcription, nuclear transport, signal transduction, and maintenance of genome integrity (1–4). A large fraction of nuclear proteins has been found to be SUMO-conjugated, in particular transcription factors and chromatin modifiers. In fact, 60–80% of all proteins involved in key nuclear functions (transcription factors, chromatin regulators, DNA damage-response factors, the spliceosome, or cell cycle regulators) were recently identified as SUMO target proteins (5). In the majority of studies of transcription, SUMOylation has been linked to repression (1, 6–8), although exceptions exist (9). Therefore, removal of SUMO conjugation is expected largely to be associated with transcriptional activation, implicating SUMO-proteases as putative players in gene activation. Our knowledge is limited of how they exert this role and within which interaction networks they operate.

The SUMO family (SUMO1–4) consists of small 10-kDa proteins that are conjugated to lysine residues in their target proteins using an enzymatic pathway consisting of E1, E2, and E3 enzymes, which resembles that of ubiquitylation. SUMO1 is only 45% identical to SUMO2 and SUMO3, whereas the latter two are almost identical and are functionally undistinguishable. The vast majority of SUMO1 exists in conjugated species, whereas a free pool of SUMO2/3 species is usually found in cells. SUMO2/3 conjugation is strongly induced in response to in vivo heat shock and oxidative stress (1–4).

SUMOylated proteins may be part of dynamic and complex interaction networks. SUMO modifications are recognized, or “read,” by proteins harboring one or several SUMO interaction motifs (SIM). This noncovalent interaction depends on a short hydrophobic core flanked by acidic amino acids ((V/I)XX(V/I)(V/I)aaa) (10).

In the SUMO system, SUMOylation is finely balanced by deSUMOylation (11–13). Proteolytic enzymes are responsible for the maturation of the SUMO precursor, for substrate

1 The abbreviations used are: PTM, post-translational modification; SUMO, small ubiquitin-like modifier; SENP, sentrin-specific protease; Seq, sequencing; CTCF, CCCTC-binding factor; PVDF, polyvinyl difluoride; GBD, Gal4 DNA-binding domain; CML, chronic myelogenous leukemia; TSS, transcription start site; SIM, SUMO interaction motif; AMC, amido-4-methylcoumarin; mAb, monoclonal antibody; GST, glutathione S-transferase; PMSF, phenylmethylsulfonyl fluoride.

J. Biol. Chem. (2018) 293(40) 15439–15454
15439

© 2018 Rodríguez-Castañeda et al. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.
deconjugation, and for depolymerizing SUMO2/3 chains (12). Six mammalian SUMO proteases have been described, SENP1–3 and SENP5–7 (12, 13). The C-terminal regions of SENP proteins encode a highly conserved catalytic domain, whereas their N-terminal domains are variable and appear to direct subcellular localization and substrate specificity (11–13).

The SUMO system is essential. Deletion of either SUMO-conjugating or deconjugating genes resulted in embryonal lethality (14–16). Dysregulation of the SUMO system has been increasingly implicated in cancer and other diseases (17–19).

SENP1 is an essential gene; its knockout in mice is embryonic lethal, causing anemia between embryonic day 13.5 and postnatal day 1 (20). This fetal anemia probably stems from deficient erythropoietin production appearing because SENP1-mediated GATA1 deSUMOylation is critical for definitive erythropoiesis (15). SENP1 was also found to be essential for the development of early T and B cells (21). However, the full function of the SENP/ULP family within the cell has yet to be determined (22–24).

Transcription depends on a dynamic chromatin structure that can respond to changes in the regulatory inputs. This dynamic is controlled through PTMs of histones and other chromatin-associated factors. Among these, SUMOylation has gained increasing importance, playing a key role in the regulation of transcription and chromatin dynamics through a variety of mechanisms (6). However, despite extensive studies, our understanding of the role of SUMOylation in chromatin dynamics remains incomplete. Several chromatin-related mechanisms have been proposed to explain the repressive effect observed for a large number of factors as a consequence of their SUMOylation. SUMO appears to recruit a diversity of chromatin-modifying enzymes and chromatin-associated proteins, including the histone deacetylase HDAC2, the histone demethylase LSD1, the histone methyltransferase SETDB1, the nucleosome remodeling ATPase Mi-2, and chromatin-associated proteins HP1, L3MBTL1, and L3MBTL2 (25–27). It has been proposed that SUMO sets up a local repressive heterochromatin (26). Even if this process is only partially understood, we know even less when it comes to how this repression is abolished or relieved. The dampening effect of SUMOylation implies that in many cases relief from SUMO repression may represent an important contribution to the transcriptional activation caused by a transcription factor.

In this work, we focus on SUMO-proteases as putative players in gene activation. We reasoned that their role in gene activation might be clarified through their interactome. By screening for interaction partners of SENP1, we identified the chromodomain helicase DNA–binding protein 3 (CHD3), implicating a novel link between deSUMOylation and chromatin remodeling. We used CRISPR-Cas9–generated KO cells in combination with ATAC-Seq and RNA-Seq to uncover a functional link between the two proteins.

Results

SENP1 interacts with CHD3

As a first step toward finding novel gene activation mechanisms dependent on SENP1, we performed a yeast two-hybrid screening of a human thymus cDNA library using a centromeric bait-plasmid to identify partners of SENP1. Even at the low expression level achieved with our single copy CEN-plasmid approach, SENP1 turned out to be toxic to yeast cells precluding ordinary screening (Fig. 1A). However, by using a protease-dead mutant of SENP1 (C603S), the toxic effects were minor, and we were able to perform a screening of $6 \times 10^7$ clones, of which 92 positive grew on various selective media.
We sequenced the cDNA of 40 of the clones with the strongest blue color on 5-bromo-4-chloro-3-indolyl β-D-galactoside (X-Gal) plates. The interaction between SENP1 and selected prey was verified in yeast by transformation and growth on reporter-selective media (Fig. 1B). Among the cDNAs with highest frequency in this screening, we found the chromatin remodeler CHD3 (Figs. 1B and 2A), which we selected for further studies because we thought CHD3 may represent an interesting novel link between the SUMO system, chromatin remodeling, and transcription.

But before we embarked on a further analysis, given that the interaction was observed in yeast cells, we performed size fractionation of nuclear extracts from K562 cells. Using Superose-6 fractionation of nuclear extracts from a derived K562 cell line expressing 3×Ty1-tagged CHD3 and a control cell line, we observed in both cases that endogenous SENP1 migrated in high-molecular weight fractions supporting its association with larger proteins or complexes (Fig. 1, C and D). CHD3 eluted as a high-molecular weight complex as expected from its association with NuRD-type complexes (28).

To confirm the interaction between SENP1 and CHD3 by independent methods, we first performed GST-pulldown assays using full-length GST–SENP1 WT and C603S mutant. The purified fusion proteins were incubated with lysate from COS-1 cells transfected with an expression plasmid for full-length CHD3. As shown in Fig. 2B, CHD3 was retained on GST–SENP1 (WT and mutant) but not on the GST control. To map in more detail the interacting regions, we performed GST pulldown assays with deletion constructs of both SENP1 and CHD3. The catalytic domain of SENP1(297–644) bound more strongly to CHD3 than its N-terminal regions (amino acids 1–296) (Fig. 2C). It appears that the minimal catalytic domain of SENP1(416–644) is sufficient for strong interaction of SENP1 with CHD3 (Fig. 2D). When GST fusions of SENP1(297–644) were used to retain subdomains of CHD3 expressed in COS-1 cells, we observed more than one region of CHD3 binding to SENP1. Both the N-terminal domain (CHD3(1–324)), the PHD-chromodomain region (CHD3(308–708)) and the C-terminal CTD-region (CHD3(1655–2000)) were retained by GST–SENP1(297–644) (Fig. 2E). In contrast, the central ATPase domain of CHD3(709–1217) and the DUF region of CHD3(1218–1654) showed no affinity for SENP1.

An additional line of evidence for the CHD3–SENP1 interaction was provided by co-immunoprecipitation assays, first using lysates from COS-1 cells transfected with 3×FLAG-SENP1 and 3×Ty1–CHD3. As shown in Fig. 2F, SENP1 was co-immunoprecipitated with CHD3 (anti-Ty1 antibody). Control transfections indicated that this interaction is specific. We then used a K562 cell line stably expressing 3×Ty1–CHD3 to perform co-immunoprecipitation assays under more stringent, semi-endogenous conditions. In K562 nuclear extracts from this stable cell line, endogenous SENP1 was co-immunoprecipitated with CHD3 as revealed by a polyclonal rabbit anti-SENP1 antibody (Fig. 2G). The level of expression of 3×Ty1–CHD3 in this stable cell line was close to the endogenous level of CHD3 in the parental K562 cells, supporting an interaction at physiological levels of both SENP1 and CHD3 (Fig. S1).

Fluorescence anisotropy experiments with a fluorescently labeled SUMO1 (SUMO1–AMC) gave evidence for the formation of a CHD3–SENP1–SUMO1 ternary complex in solution (Fig. 2H). CHD3 has been reported to bind SUMO1 (29). Hence, we monitored the binding of SUMO1–AMC to CHD3 as fluorescence anisotropy. Upon increasing concentrations of CHD3, we observed the expected change in anisotropy (Fig. 2H). If CHD3 in addition were binding to SENP1, we expected an increase in anisotropy because of the increased size of the ternary complex. To avoid too strong a binding of SUMO1 to CHD3, we made use of a CHD3 mutant where its SUMO interaction motif close to its C terminus was mutated (amino acid positions 1994–1997 changed from VICI to AACA). We also used a catalytic dead mutant of SENP1 (C603S) to avoid cleavage of the AMC fluorophore under these conditions, and we used only the catalytic domain of SENP1(297–644), binding CHD3 strongly (Fig. 2C). The shift in the CHD3-titration curve upon addition of a fixed amount of SENP1 suggests that SUMO1–AMC was binding to a larger complex when CHD3 and SENP1 were combined compared to when CHD3 was titrated alone, supporting the interaction of the two proteins in solution.

Because CHD3 operates on chromatin, we tested whether the remodeler was able to recruit SENP1 to chromatin. For this purpose, we performed ChIP experiments in the HEK293-c1 cell line (26) transfected with a Gal–CHD3 fusion and monitored the occupancy of SENP1 both at the Gal–CHD3-bound site (5×Gal4 response-element promoter) and at a more distant locus (NCOA5 intron) serving as background reference. SENP1 was not recruited to any of these sites in the presence of the control Gal4 DNA-binding domain (GBD) only. However, in the presence of the Gal–CHD3 fusion protein, which becomes directed to the Gal4-responsive promoter, the recruitment of SENP1 was evident (Fig. 3). These observations are in line with the interaction experiments and consistent with the hypothesis that SENP1 and CHD3 interact in a chromatin context where SENP1 becomes recruited to chromatin-associated CHD3. Taken together, these independent interaction assays all supported the validity of an interaction between SENP1 and CHD3 both in vitro and in vivo involving the catalytic domain of SENP1 and regions of CHD3.

**SENP1 and CHD3 affect shared loci in the genome**

To address the functional implications of the interaction between SENP1 and CHD3, we focused first on the effects on chromatin features. We reasoned that because CHD3 is a chromatin remodeler, the accessibility of some loci should be affected by loss of CHD3. Furthermore, if CHD3 and SENP1 interact in a way that affects the function of CHD3, there should also be some shared loci where accessibility is affected by loss of each of the two proteins. For this purpose, we made use of HAP1 cells in which the genes for either SENP1 or CHD3 were inactivated by CRISPR-Cas9–generated frameshift mutations into the coding sequence of the respective genes. HAP1 is a near-haploid human cell line that was derived from the male chronic myelogenous leukemia (CML) cell line KBM-7 (30). The characterization of the KO cell lines showed that they both lacked the full-length proteins (Fig. S2). However, they appear
to express a reduced amount of a truncated protein (20% for the truncated CHD3, less for the truncated SENP1), suggesting that there is an alternative start codon downstream of the primary ATG or that an alternatively spliced transcript is formed that does not include the edited exon. Hence, the KO cell lines used here may be regarded as a KO for the full-length protein but a knockdown for the total pool of proteins caused by expressed isoforms.

The WT reference cell line and the two KO HAP1 cell lines (CHD3-KO and SENP1-KO) were analyzed genome-wide for chromatin accessibility using the ATAC-Seq method. A total of about 60,000 ATAC signals were found in each of the three cell lines. (For details on statistical correlation of ATAC-Seq replicates, see Fig. S3.) Fig. 4A shows an overview of the differential chromatin accessibility based on the number of sites that exhibit a $\geq 50\%$ fold change in ATAC signals in the KO cell lines relative to the control WT cell line. Using this threshold, the CHD3-KO cells showed differential peaks at 3026 sites, a majority of which showed increased chromatin accessibility after knockdown (2364), in line with a main role of CHD3 as a repressor of transcription. However, a significant fraction showed decreased chromatin accessibility (662), suggesting that CHD3 may also contribute to open chromatin at specific sites. Because the role of SENP1 on chromatin is less well characterized, the expected profile for the SENP1-KO was not obvious. However, it turned out to be very similar to that of CHD3-KO. The SENP1-KO cells showed differential peaks at 2909 sites, a majority of which showed increased chromatin accessibility after knockdown (2209), suggesting a main role of SENP1 at chromatin as restricting openness. However, also in this case, a significant fraction showed decreased chromatin accessibility (700). Finally, and most important, was the observation of a significant overlap between the differentially accessible regions (1716 sites) between SENP1-KO (both increased and decreased) and CHD3-KO (both increased and decreased). The most frequent type of genomic region affected by both deletions was “other intergenic” in which most enhancers are characterized, the expected profile for the SENP1-KO was not obvious. However, it turned out to be very similar to that of CHD3-KO. The SENP1-KO cells showed differential peaks at 2909 sites, a majority of which showed increased chromatin accessibility after knockdown (2209), suggesting a main role of SENP1 at chromatin as restricting openness. However, also in this case, a significant fraction showed decreased chromatin accessibility (700). Finally, and most important, was the observation of a significant overlap between the differentially accessible regions (1716 sites) between SENP1-KO (both increased and decreased) and CHD3-KO (both increased and decreased).

Peaks that are located close to the TSS are positively correlated with ATAC signals. Hence, we analyzed the ATAC peaks according to the SUMO2/3 peaks found in K562 cells, the resulting heatmap of the average ATAC-Seq signals showed an increased openness in the two KO strains around the TSS with a peak just upstream of the TSS (Fig. 4B). This suggests that for the subtraction of ATAC-Seq peaks that are close to a TSS, both CHD3 and SENP1 appear to affect the nucleosome-free regions of promoters. We show examples of this effect, where in the CHD3-KO and SENP1-KO cell lines chromatin is more open next to a TSS (BHLHE22, SERTAD4, CTGF, and TFFP12), and one case represents the less frequent opposite effect (RHOB) (Fig. 4C and Fig. S4). This suggests that CHD3 is involved in keeping a significant fraction of loci closed in a way that also depends on associated SENP1.

Unfortunately, there are no public genome-wide ChIP-Seq data on HAP1 cells. To evaluate the relevance of our ATAC profiling, we took advantage of the fact that both HAP1 cells and K562 cells are CML-derived cell lines, so we reasoned that ChIP-Seq data from K562 might be used as a proxy to evaluate whether the ATAC sites found in HAP1 cells correlate with relevant ChIP-Seq profiles. Unfortunately, genome-wide ChIP-Seq data for CHD3 and SENP1 are lacking. However, we reasoned that an enzyme needs a substrate, so the location of SENP1 along chromatin might show a correlation with the location of SUMO associated with chromatin. Niskanen et al. (31) analyzed chromatin occupancy of SUMO-2/3-modified proteins in K562 cells using ChIP-Seq and concluded that heat-shock SUMOylation targets promoters and enhancers of actively transcribed genes, thereby restricting the transcriptional activity of the induced genes. When we compared the 1716 shared ATAC peaks with the SUMO-2/3 peaks from K562 (control, not heat shock), a majority (1084 peaks, i.e. 63%) of the regions overlap with SUMO-2/3 peaks in K562 cells (Fig. 5). The overlap shown in Fig. 5A is based on shared peak annotations localizing to specific genes. A comparable result was obtained with another calculation based on physical overlaps of peaks (Fig. S5). When we used the SUMO data and centered all the ATAC peaks according to the SUMO2/3 peaks found in K562 cells, the resulting heatmap of the average ATAC-Seq signals showed an increase in the ATAC profile centered over the SUMO peaks (Fig. 5). Given that HAP1 cells and K562 cells are not identical, we find this overlap indicative of a link between the fraction of SENP1 and of SUMO associated with chromatin.

**Figure 2. CHD3 interacts with SENP1.** A. A human CHD3 and SENP1 are depicted with their domain structures. B–E, GST pulldown binding assays were performed with different GST protein domains and 3xFLAG–CHD3 from transfected COS-1 cells. The GST fusion proteins used were full-length versions of SENP1 (panel B), and the indicated deletions of SENP1 (panels C, D, and E). In panels B, C, and D, binding of the GST proteins to full-length CHD3 was monitored, while binding to deletions of 3xFLAG–CHD3 was monitored in panel E. 24 h after transfection, the COS-1 cells were lysed in KAc-interaction buffer, and the lysates were incubated with comparable amounts of the different GST fusion proteins bound to GSH beads. The bound proteins were separated by SDS-PAGE, and SENP1 was revealed by immunoblotting (panel B). Where the co-IP band was only 0.01% of the total input. From a measure of the pixels in the bands in the upper panel, we estimated that in the right part from 3xFLAG–CHD3-expressing cells, 17% in Ty1–CHD3-expressing cells, 1.7% of the total input with Ty1–Empty stable K562 cell line served as control (panel E). BHLHE22, SERTAD4, CTGF, and TFFP12, and one case represents the less frequent opposite effect (RHOB).
enrichment of known motifs (Fig. 6B), the two with the highest $p$ values (estimated from the frequency of the found known motif in the target set relative to the background frequency of the same motif in the background set) were the following: 1) motifs for the pluripotency factors OCT4–SOX2–TCF–NANOG (328 sites, $p = 1 \times 10^{-30}$), and 2) motifs for CTCF (142 sites, $p = 2 \times 10^{-13}$) and for CTCFL/BORIS (189 sites, $p = 1 \times 10^{-9}$), a paralog of CTCF having a DNA-binding specificity identical to that of CTCF (33). The latter is reflected in 102 sites being shared between CTCF and CTCFL in our dataset. An extended list is shown in Fig. S6.

To evaluate the relevance of these motifs, we again took advantage of the fact that both HAP1 cells and K562 cells are CML-derived cell lines and that CTCF occupancy often is conserved between different cell types (34–36). Hence, we compared the 142 sites affected by both SENP1 and CHD3 KO in HAP1 cells (and harboring a CTCF motif) with available ChIP-Seq profiles for CTCF from K562 cells. As shown in the Venn diagram in Fig. 6C (upper left) and illustrated by example profiles in Fig. S7, the vast majority ($i.e.$ 88%) of the 142 regions are in fact occupied by CTCF in K562 cells. When all the 1716 shared ATAC peaks were compared with CTCF ChIP peaks in K562 (Fig. 6C, lower diagram), again a high percentage (1096 peaks, 64% of the total) overlapped, suggesting a significant association between CTCF and the sites where CHD3 and SENP1 cooperate. The overlap shown in Fig. 6C is based on shared peak annotations localizing to specific genes. A comparable result was obtained with another calculation based on physical overlaps of peaks (Fig. S5). Of note, 87% of the 1096 overlapping peaks also shared a SUMO-2/3 ChIP peak in K562 cells (Fig. 6C, upper right), in line with an association between SENP1 and SUMO at chromatin. When all the ATAC peaks were centered according to the CTCF peaks found in K562 cells, the resulting heatmap of the average ATAC-Seq signals showed an increase in the ATAC profile centered over the CTCF peaks (Fig. 6D). We also performed a “functional term analysis” of this subgroup ($i.e.$ genes closest to the ATAC peak regions of the 142 sites) and saw an enrichment of various processes, in particular linked to immature B cell differentiation and regulation of mRNA splicing (Fig. S8). Taken together, this suggests that one important group of regions where CHD3 and SENP1 operate together is CTCF-occupied sites.

A similar analysis of the link to the motifs with the highest $p$ value was not possible because the associated factors are not expressed in K562 cells, although at least SOX2 is expressed in HAP1. OCT4, SOX2, and NANOG are pluripotency factors expressed in embryonic stem cells. However, we compared some factors on the list that are well expressed in K562, NRF2, NF-E2, and Bach1. The HOMER analysis revealed 58 peaks ($p = 0.007$) with motifs for NRF2/GABPA (EntrezGene ID:2551) (70). The ATAC peaks centered clearly around regions enriched for binding of this factor (Fig. 7). A similar comparison with NF-E2 (59 sites, $p = 0.02$), also highly expressed in K562 (EntrezGene ID:4778) (70), however, showed only a weak, less convincing correlation (Fig. S9). The same poor correlation was true for Bach1 (63 peaks, $p = 0.002$) (Fig. S10). The latter illustrates that the ATAC peak regions are found enriched only at a selection of open sites.

**Figure 3. CHD3 recruits SENP1 to the chromatin.** ChIP assays were performed in the HEK293-c1 cell line containing an integrated 5xGAL4-Luciferase gene (26). Cells were transfected with plasmids encoding the Gal4 DNA-binding domain (GBD), GBD–CHD3, and 3×FLAG–SENP1 in the combinations indicated. A, illustration showing the genomic loci in the NCOA5 gene where the 5xGAL4-Luciferase gene is integrated. B, ChIP assay against GBD–SENP1 in the combinations 3×FLAG–SENP1, GBD, and GBD–CHD3, with antibody against the Gal4 DNA-binding domain (IB) and GAPDH, with antibody against the Gal4 DNA-binding domain (IB). The mean of three biological replicates is shown, with error bars indicating standard error of the mean. C, representative immunoblot of the transfections.
In addition to genome-wide comparison of our ATAC-Seq data to publicly available ChIP-Seq data for different factors, we also took advantage of DNase-Seq data in HAP1 cells (ENCSR620QNS), which is the only public data set to date that is generated using HAP1 cells. Similar comparisons were done, where we centered ATAC-Seq signals on DNase-Seq peaks from HAP1 cells. The resulting comparison revealed as expected enrichment of ATAC-Seq signals on DNase-Seq peaks (Fig. S11).

**SENP1 and CHD3 affect the expression of shared genes in the genome**

To further analyze the functional implications of the interaction between SENP1 and CHD3, we reasoned that their shared effect on accessibility of many regions would imply a shared effect on the expression of some genes. We therefore performed RNA-Seq analysis of the same variants of the HAP1 cells as used for the ATAC-Seq analysis. Hence, RNA was isolated from three independent biological replicates of SENP1-KO, CHD3-KO, and WT reference HAP1 cells, delivered to high-throughput sequencing and subjected to downstream statistical processing. Transcriptome-wide fold change of differentially expressed genes for the knockout cell lines relative to the control is presented in volcano plots (Fig. S12). Analysis of the sequencing data revealed that SENP1-KO had a significant change in the expression of 2245 genes, whereas the CHD3-KO had a significant change in the expression of 808 genes (Fig. 8). 43% of the latter (351 genes) were also among those affected in SENP1-KO cells, supporting the hypothesis that SENP1 affects the function of CHD3 at a significant fraction of genes. SENP1 clearly also affects a large number of genes through other mechanisms than through CHD3. We noticed that all combinations of up- and down-regulation were found in comparable numbers among the shared genes, probably because both direct and indirect effects are to be expected in this type of analysis. We assume that this is the reason why the RNA-Seq analysis gave a more diverse pattern than the ATAC-seq. One may argue that opposite expression patterns are more likely to be caused by indirect effects. In support of this, we observed a higher correlation between genes associated with ATAC-Seq peaks and genes with altered expression when we compared genes that were similarly regulated (both up- or both down-regulated) than for oppositely regulated genes. In the first case, visual inspection of the ATAC tracks close to each gene with altered expression when we compared genes that were similarly regulated (both up- or both down-regulated) than for oppositely regulated genes. In the first case, visual inspection of the ATAC tracks close to each gene with altered expression when we compared genes that were similarly regulated (both up- or both down-regulated) than for oppositely regulated genes.
Finally, to get an idea of which functions were involved, we performed a gene ontology (GO) analysis of the shared genes. A quite diverse pattern of functions was found in the groups with opposite effects of the two knockouts. In the group of genes where SENP1-KO and CHD3-KO both were associated with down-regulation, we observed an enrichment for functions linked to growth and signaling. In the group of genes where SENP1-KO and CHD3-KO both were associated with up-regulation, we observed an enrichment for a signaling pathway, but also to histone modifications (Fig. S13).

**Discussion**

SUMO proteome analysis has revealed the involvement of SUMO in a wide range of nuclear functions, including transcription and chromatin remodeling (5, 37). As is well known from extensive studies of phosphorylation, acetylation, and methylation of nuclear proteins, the processes of de-modifications are equally important as the modification processes. Our objective in this study was to focus on the deSUMOylation process and seek a better understanding through the identification of novel interaction partners of the SENP1 enzyme. We
SEN1–CHD3 interaction and cooperation

A. Increased chromatin accessibility

B. Decreased chromatin accessibility

B. Motif | Name | P-value | # target sequences with motif
--- | --- | --- | ---
| | OCT4-POX2-TCF-POU,Homeoboxes,JIMG3/mES- | 1.00x10⁻¹⁰ | 328 |
| | NANOG-Homeoboxes,JIMG3/mES- | 1.00x10⁻¹⁰ | 142 |
| | CTCF(S/JCD4)-CTCF-ChIP-ChIP-Seq(Burkler et al.)Homer | 1.00x10⁻¹⁰ | 109 |

C. ATAC peaks with shared, increased accessibility and CTCF motif

D. CTCF ChIP-seq

CTCF ChIP-seq

ATAC

ctrl ATAC | CHD3-KO ATAC | SENP1-KO ATAC

J. Biol. Chem. (2018) 293(40) 15439–15454
observed that SENP1 from a nuclear extract of K562 cells migrates as a rather high-molecular weight entity (Fig. 1, C and D). Using a stringent version of the yeast two-hybrid method and a nontoxic mutant of SENP1, we identified the chromatin remodeler CHD3 as a novel interaction partner of SENP1 (Fig. 1B). The interaction was validated in vitro by GST-pulldown assays, co-immunoprecipitations, and fluorescence anisotropy titrations (Fig. 2). The interaction was also validated in vivo by a ChIP assay where we directed CHD3 to a specific locus through fusion to a Gal4–DNA-binding domain and observed that SENP1 became enriched at the same locus (Fig. 3). We also mapped the domains involved as the catalytic domain of SENP1 and at least two regions of CHD3, its C-terminal region and the N-terminal region, including its PHD and CHD domains (Fig. 2).

Figure 6. Correlation between open regions affected by CHD3 and SENP1 and chromatin-bound CTCF. A, Venn diagram showing the number of overlapping peaks (n = 1366) between differential ATAC peak regions in SENP1-KO and CHD3-KO having increased chromatin accessibility (left). The right Venn diagram shows the same overlap for differential ATAC peak regions with decreased chromatin accessibility (n = 350). B, motif enrichment of the subgroup with shared increased chromatin-accessible regions (n = 1366). The specific binding motifs are arranged in descending order based on their p value. Motif analysis around peak regions of the shared differential ATAC subgroup with increased chromatin accessibility (n = 1366) was done using the HOMER program (32). The small Venn diagram below shows the overlap of motif instances (n = 102) between two of the most significantly known motifs enriched among the shared differential ATAC subgroup (n = 1366). Motif regions with CTCF binding (n = 142) and with CTCFL binding (n = 189) was used to calculate the overlapping regions. C, Venn diagram showing the number of overlapping regions (n = 125) between motif regions with CTCF binding (n = 142), extracted from enriched motifs above, and CTCF ChIP-Seq peaks from K562 (ENCSR000EGM). The lower Venn diagram shows overlapping regions (n = 1096) between the same CTCF ChIP-Seq peaks from K562 and the ATAC-Seq subgroup with shared differentially accessible regions (n = 1716). The upper right Venn diagram shows the overlapping regions (n = 953) between the subset that is shared between ATAC differential accessible regions and CTCF peaks above (n = 1096) and that of SUMO2/3 peaks (GSE66448) (n = 1084) (from Fig. 5A). The overlapping regions were obtained by annotating the relevant files (i.e. extracted motif instances from ATAC peaks, public CTCF peaks, and the jointly affected differential ATAC regions) using the HOMER program annotatePeaks.pl (32). The annotated files were then used to obtain the corresponding pairwise intersections of peak regions that are annotated to promoter ID of the nearest gene. A separate analysis of the pairwise intersection using a different tool representing physical overlaps is shown in Fig. S5. D, heatmap showing the average ATAC-Seq signal centered on CTCF-binding sites along with a line plot showing the intensity of the centered average ATAC signal. Similarly, a heatmap showing average CTCF ChIP-Seq signal centered on CTCF-binding sites along with a line plot showing the intensity of the centered average ChIP-Seq signal. Public ChIP-Seq data for CTCF in K562 (ENCSR000EGM) from ENCODE was used as regions for calculating enrichment of the ATAC signal at and ±3 kb around CTCF-binding sites. Heatmaps and line plots were made using deepTools2 (67).
To test the functional relevance of this novel interaction, we took a global approach and used ATAC-Seq profiling of HAP1 cells in which either CHD3 or SENP1 were knocked out. The sites where the accessibility of chromatin depended on CHD3 largely overlapped with those where the accessibility of chromatin depended on SENP1, strongly supporting the functional relevance of their interaction (Fig. 4). A more indirect analysis of the transcriptomes of the KO cells still showed that a significant fraction of the genes affected by loss of CHD3 were also affected by loss of SENP1 (Fig. 8). We conclude that the SUMO system and the chromatin-remodeling system involving CHD3 are linked and operate together at specific chromatin loci.

Several links between the SUMO system and chromatin remodeling have already been reported for other remodelers, such as the yeast chromatin-remodeling Isw1a complex (38) and the INO80 chromatin-remodeling complex (39), both of which appear to be regulated by SUMOylation.

Our findings raise several questions on how SUMOylation and deSUMOylation processes cooperate with chromatin-remodeling processes. The simplest model for explaining our observations would be that CHD3 was SUMOylated and associated with SENP1 because of being a substrate. CHD3 is well known to be involved in SUMO binding, acting as a SUMO-dependent corepressor and contributing to the repressive effect often observed after SUMOylation of transcription factors (26, 27, 41). A well-studied example is the repressor protein KAP1, the SUMOylation of which is required for KAP1-mediated gene silencing. KAP1 seems to function by directly recruiting the SETDB1 histone methyltransferase and CHD3 via SUMO-interacting motifs (40). Less is known about SUMO modification of CHD3 itself. However, according to the proteome studies of Hendricks et al. (41), three SUMOylation sites were identified in CHD3 (Lys-627, Lys-1238, and Lys-1308), whereas eight sites were found in the paralog CHD4. If and how the activity of CHD3 is modulated through these modifications is not known. Recently, another SUMO conjugation site in CHD3 (Mi2*/H9251) was identified in Lys-1971 (42). Based on various functional studies, the authors concluded that the transcription factor hDREF might incite transcriptional activation by SUMOylating CHD3, resulting in its dissociation from chromatin. Combined with our observations, an attractive hypothesis would be that SENP1 through deSUMOylation of CHD3 would enhance its chromatin association. This hypothesis also implies that CHD3 would be less chromatin-associated in the absence of SENP1.

However, several of our interaction assays were performed with recombinant proteins that are unmodified, so the SENP1–CHD3 interaction is clearly not dependent on SUMO modification. It appears that CHD3 and SENP1 interact more strongly and specifically than a transient enzyme–substrate interaction. Another attractive hypothesis is based on the concept of “group SUMOylation” (43), assuming that SUMOylation controls the activity not only of individual proteins but also of entire complexes.

Figure 8. RNA-Seq changes in CHD3-KO and SENP1-KO HAP1 cells. A, heatmap showing hierarchical clustering of significant differentially regulated genes shared between SENP1-KO and CHD3-KO (n = 351), with each row representing a gene. The cluster heatmap was generated using ClustVis webtool (41). B, significant differentially regulated genes upon CHD3-KO and SENP1-KO and the intersection between them (n = 351). C, proportion of different subgroups among the shared affected genes by CHD3-KO and SENP1-KO, the number of shared genes that were both down-regulated (n = 82), both up-regulated (n = 80), up-regulated in SENP1-KO, and down-regulated in CHD3-KO (n = 66), and vice versa (n = 123). Differential gene expression was calculated using cuffdiff (69).


**SEN1–CHD3 interaction and cooperation**

plexes. Here, the scenario would be that when a locus needs to be remodeled, as it occurs during changes in gene programs, one may imagine a coordinated action where CHD3 is recruited to SUMOylated clusters in chromatin (possibly enhanced by SENP1), followed by remodeling the local chromatin. At the same time, SENP1 recruited by CHD3 will remove SUMO modifications of several proteins or complexes in the same region, leading to coordinated reprogramming.

The latter scenario is also interesting in light of our finding of a link to CTCF, where a significant subtraction of the chromatin sites that were affected by loss of both SENP1 and CHD3 were also enriched in CTCF-binding motifs. Combined with a correlation with K562 CTCF ChIP-Seq data, supporting actual binding of CTCF to these sites, this suggests that CHD3 and SENP1 operate together at some CTCF-occupied sites. Because CTCF is a key component of the structures that determine chromatin organization, one may even imagine a cooperation between CHD3 and SENP1 contributing to the regulation of chromatin architecture during processes where gene programs need to be modulated. Whether CHD3 or SENP1 is directly recruited to chromatin by CTCF is not known, but it has been reported that CHD7 and CHD8 in fact associate with CTCF ([44, 45]). Other chromatin remodelers have also been observed to operate and organize arrays of nucleosomes adjacent to CTCF-bound sites, promoting CTCF binding ([46]). Moreover, CTCF is itself SUMOylated at two major sites ([47]), affecting its transcriptional and chromatin opening activity ([49, 50]). This makes CTCF a putative substrate for SENP1. The functional implications of these interactions and cooperation require further studies.

The link between SUMO, CTCF, and chromatin architecture, including enhancer–promoter looping, will be a highly interesting focus for future research. A recent study by Whalen et al. ([48]), where they developed a computational method for reconstructing regulatory landscapes from diverse features along the genome, concluded that most of this signature is not proximal to the enhancers and promoters but instead decorates the looping DNA. In particular, they found that SUMOylation in the window between an enhancer and a promoter was a top predictor of interactions, nearly as important as CTCF ([48]).

We also found it intriguing that the most significant motif enrichment indicated a link to pluripotency factors or other transcription factors playing a role in development. The model here would be that a specific transcription factor recruits CHD3 to assist in remodeling the local chromatin, whereas SENP1 performs its group deSUMOylation leading to a coordinated action. Interestingly, the pluripotency factors are also pioneer factors with a key role in making a region accessible to other transcription factors ([49]). It is still a debate whether they perform this only by themselves or by recruiting chromatin remodelers ([50]). In the latter case, recruiting CHD3 would, according to our findings, also imply recruitment of SENP1 leading to deSUMOylation. An example of a transcription factor operating both as a pioneer factor and associated with CHD3 is c-Myb ([51, 52]).

In summary, the interaction between SENP1 and CHD3 studied in this work suggests a novel level of coordinated control of gene expression where chromatin remodeling and deSUMOylation cooperate at specific genomic loci. Our studies have pointed to unexplored links with deSUMOylation, chromatin remodeling, CTCF, SUMO, and pioneer factors. Future studies will be necessary to understand the molecular details of the cooperation between these nuclear systems.

**Experimental procedures**

**Cell cultures**

The following four cell lines were used: COS-1 (ATCC® CRL-1650™ Cercopithecus aethiops kidney); HEK293 (ATCC® CRL-1573™ Homo sapiens embryonic kidney); K562 (ATCC® CCL-243™ H. sapiens bone marrow, chronic myelogenous leukemia); and HAP1 cells (near-haploid cell line derived from the male CML cell line KBM-7, Horizon). HAP1 knockout (KO) cell lines for CHD3 and SENP1, and a parental control cell line were obtained from Horizon Discovery. The cells were grown at 37 °C and 5% CO₂. The COS-1 and K562 cells were grown and transfected with the indicated plasmids as described previously ([53, 54]). The HAP1 cell cultures were maintained in Iscove’s modified Dulbecco’s medium containing 10% fetal calf serum and 1% penicillin/streptomycin. K562 cells stably expressing a tagged CHD3 variant (3×TY1–CHD3) were selected by G418 for 2 weeks before selecting single clones for 1 week. Stable expression was confirmed by Western blotting.

**Plasmid construction**

The pDBT–hSENP1 WT and C603S derivative were constructed by subcloning a human SENP1 cDNA ([53]) into the pDBT vector. We discovered four point mutations in our original SENP1 cDNA that were repaired prior to designing the various SENP1-containing plasmids. The C603S mutant derivative of SENP1 was generated by QuikChange site-directed mutagenesis. The various GST–SENP1 fusion proteins were PCR-cloned into pGEX-6P2 vector using BamHI and NotI. Human CHD3 cDNA from the construct pCIneoB-3×FLAG–CHD3 ([52]) was transferred using SacII and NotI to the pEF1neo-3×TY1 vector to express a 3×TY1-tagged version of CHD3. The plasmid expressing a Gal4 fusion to CHD3 has been described ([52]). All constructs were verified by DNA sequencing.

**Antibodies**

For immunoblot detection, the following antibodies were used: mouse anti-FLAG M2 mAb (F3165, Sigma); mouse antiproliferating cell nuclear antigen (PC-10, sc-56 Santa Cruz Biotechnology, Inc.); mouse anti-GAPDH (AM4300, Invitrogen); rabbit anti-GBD (06-06, Upstate Biotechnology); rabbit anti-CHD3 (ab114100 and ab109195, Abcam); rabbit anti-SENP1 (ab108981, Abcam); and from Li-Cor Biosciences, IRDye 800CW anti-mouse (926-32212); IRDye 680RD anti-mouse (926-68072); IRDye 680RD anti-rabbit (92668073); and IRDye 800CW anti-rabbit (926-32213). The anti-Ty1 monoclonal mouse antibody was produced in our laboratory from a hybridoma cell line ([55]).
Co-immunoprecipitations were performed essentially as described (58) using the F-buffer replaced with a KAc-interaction buffer (150 mM KAc, 20 mM HEPES, pH 7.4, 10% glycerol, 0.2% Triton X-100, 1 mM DTT, 1 × Complete protease inhibitor, Roche Applied Science) or with a NaCl-interaction buffer (50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% (v/v) Triton X-100, 1 mM DTT, 1 mM PMSF, and 1 × Complete protease inhibitor), using total cell extracts from COS-1 cells transfected with the indicated expression constructs. The proteins retained on the GST-Sepharose beads were analyzed on a 4–15% Criterion SDS-polyacrylamide gradient gel. The membrane was blocked with LI-COR blocking solution (product no. 927-50010) for 1 h, probed with anti-FLAG antibody in LI-COR blocking solution over- night at 4 °C, and washed before being probed with LI-COR IRDye 680RD anti-mouse secondary antibody in LI-COR blocking solution for 1 h. The PVDF membrane was scanned with the LI-COR Odyssey Imaging System.

Expression and purification of 3 × FLAG–CHD3 protein from COS-1 cells

Two 15-cm plates with COS-1 cells were transfected with 132 μg of pcDNA3–3 × FLAG–CHD3 or pcDNA3–3 × FLAG–CHD3–SIM1994–AACA constructs using polyethyleneimine (23966, Polysciences, Inc.). 24 h after transfection, the cells were washed and resuspended in 1.5 ml of BC100 + 0.05% Nonidet P-40. The cell suspension was sonicated (Up400s, Hielscher Ultrasons GmbH) four times at 50% intensity for 15 s. The cell debris was removed (13,400 rpm for 20 min), and the supernatant was flash-frozen in liquid nitrogen and stored at −80 °C until purification.

The FLAG–CHD3 proteins were purified by affinity chromatography. First, 125 μl of FLAG M2-magnetic beads (M8823, Sigma) were added and incubated at 4 °C with rotation. The beads were washed once with 2 ml of BC100 + 0.05% Nonidet P-40 and once with 2 ml of BC100 + 0.05% Nonidet P-40. The FLAG–CHD3 proteins were eluted with 100 μl of BC100 + 0.05% Nonidet P-40 + 0.5 mg/ml FLAG peptide (GenScript HK Ltd.). The eluted proteins were separated on a 4–15% Criterion Gel, transferred to a PVDF membrane, and detected with anti-FLAG antibody (mouse monoclonal).

Expression and purification of SENP1

Recombinant SENP1 was expressed as a GST fusion protein in E. coli BL21 cells using standard methods. The GST fusion tag was cleaved on column with 40 units of PreScission protease (27-0843-01, GE Healthcare) in the following buffer: 50 mM Tris–HCl, pH 7.0, 150 mM NaCl, 1 mM EDTA, and 1 mM DTT. The cleavage was done overnight at 4 °C. The cleaved protein was further purified by gel-filtration chromatography on a Superdex 75 column.

Preparation of K562 nuclear extract

The methodology described in Wright et al. (60) was followed. K562 cells were grown to confluency and processed essentially as described. The clear supernatant after the ammonium sulfate precipitation was subjected to dialysis (rather than column desalting), against Buffer C (25 mM HEPES, pH 7.6, 150 mM NaCl, 12.5 mM MgCl₂, 0.1 mM EDTA, 10% (v/v) glycerol, 1 mM DTT, 0.2 mM PMSF, and Complete protease inhibitors). The extract was finally centrifuged at 16,000 rpm for 5 min at 4 °C and flash-frozen in liquid nitrogen.

Yeast two-hybrid screening

The two-hybrid screening was performed by mating as described previously (52, 56–58), using as bait the CEN plasmid pDBT–hSENP1–C603S pretransformed in the Y187 yeast strain and mated with the PJ69-4A strain pretransformed with a human thymus cDNA library. The interactions were confirmed by transformation of pDBT, pDBT–hSENP1, and pDBT–hSENP1–C603S and the rescued interaction candidates in pACT2 into yeast strains of opposite mating type followed by mating. Diploids were grown on yeast minimal medium lacking the selection amino acids or adenine.

GST-binding assay

GST and GST fusion proteins were expressed in Escherichia coli, as described previously (59). GST pulldown assays were performed essentially as described (52) but with the F-buffer replaced with a KAc-interaction buffer (150 mM KAc, 20 mM HEPES, pH 7.4, 10% glycerol, 0.2% Triton X-100, 1 mM DTT, 1 × Complete protease inhibitor, Roche Applied Science) or with a NaCl-interaction buffer (50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% (v/v) Triton X-100, 1 mM DTT, 1 mM PMSF, and 1 × Complete protease inhibitor), using total cell extracts from COS-1 cells transfected with the indicated expression constructs. The proteins retained on the GST-Sepharose beads were analyzed on a 4–15% Criterion SDS-polyacrylamide gradient gel. The membrane was blocked with LI-COR blocking solution (product no. 927-50010) for 1 h, probed with anti-FLAG antibody in LI-COR blocking solution overnight at 4 °C, and washed before being probed with LI-COR IRDye 680RD anti-mouse secondary antibody in LI-COR blocking solution for 1 h. After washing with TBS-T, the PVDF membrane was scanned with the LI-COR Odyssey® CLx Imaging System.

Superose-6 fractionation of K562 nuclear extracts

The Superose-6 column was equilibrated in BC200 buffer (25 mM HEPES, pH 7.6, 200 mM NaCl, 1 mM MgCl₂, 0.5 mM EGTA, 0.1 mM EDTA, 10% (v/v) glycerol, 1 mM DTT, and 2 mM PMSF) filtered through a 0.2-μm membrane. 500 μl of the K562 nuclear extract were injected (flow rate 0.3 ml/min). The 0.5-ml fractions were frozen in liquid nitrogen and stored at −80 °C. Before analysis of the fractions by SDS-PAGE, they were precipitated with TCA to a final concentration of 20%, incubated for 10 min on ice, and centrifuged at 13,000 rpm at 4 °C for 10 min. The pellets were washed once with 1500 μl of ice-cold acetone. The protein pellets were dried at room temperature, resuspended in 1 × SDS-PAGE loading buffer before separation on a 4–15% Criterion Gel, transferred to PVDF, and immunoblotted with the desired primary antibodies.
**SEN1–CHD3 interaction and cooperation**

**Protein–protein interaction studies using fluorescence anisotropy**

The binding of SENP1 and CHD3 to SUMO1–AMC (UL-551, Boston Biochem) was followed with fluorescence anisotropy in the following buffer: 25 mM HEPES, 200 mM NaCl, 1 mM DTT, pH 7.6, using a PerkinElmer Life Sciences LS-50 fluorescence spectrometer with excitation at 380 nm and emission recorded at 460 nm. For binding of SENP1 (297–640) to SUMO1–AMC, the catalytic dead C603S mutant was used. For CHD3, we used the full-length FLAG-tagged protein (affinity-purified) but harboring a mutant in the SUMO1-interaction motif (SIM, at amino acids 1994–1997), with weaker SUMO binding that facilitated the titration. The binding of FLAG–CHD3 1994 SIM mutant proteins to SUMO1–AMC was measured at a SUMO1–AMC concentration of 200 pm.

**ChiP**

A HEK293 reporter cell line harboring a 5×GRE Gal4-luciferase reporter integrated transgene (26) was co-transfected with an HA-tagged Gal-fusion derivative of CHD3 and a 3×FLAG-tagged SENP1. The ChiP analysis was performed as described previously (61).

**RNA-Seq and analysis**

Total RNA was isolated from HAP1 cell lines using an RNA isolation kit (Qiagen-RNeasy mini kit). The quality and quantity of total RNA were determined using NanoDrop (ThermoFisher Scientific) and agarose gel electrophoresis, respectively. RNA samples were delivered for sequencing to the Norwegian sequencing center, Oslo, Norway, where libraries were prepared using strand-specific TruSeq™ library preparation kit. Transcriptomic data for the three cell lines with three biological replicates were generated using Illumina HiSeq 4000 sequencer, where 150-bp paired-end reads were obtained. The subsequent bioinformatics analysis is detailed in the supporting Materials and methods. Data have been made publicly available under GEO (accession number GSE111272).

**ATAC sequencing and analysis**

ATAC libraries for the HAP1 cell lines were made as described previously (62). Ad1 noMX and Ad2.1–2.12 bar-coded primers were used from Ref. 63. Crude nuclei were prepared from 150,000 cells per cell line, and the amount of all reagents used in the transposition assay were doubled relative to Ref. 62.

Background regions that are normally Tn5 transposase-accessible were obtained by isolating genomic DNA from HAP1 control cell lines using GenElute™ mammalian genomic DNA miniprep kit (Sigma). This was followed by the transposition reaction and ATAC library preparation as described above. ATAC libraries were delivered to the Norwegian sequencing center, Oslo, Norway, where library quality was determined and sequenced. Three biological replicates were used to generate 40-bp paired-end reads using the Illumina NextSeq 500 sequencer. The bioinformatics analysis is detailed in the supporting Materials and methods. Data have been publicly available through GEO (accession number GSE111047).

**Public datasets**

ChiP-Seq datasets from K562 cells that were mapped to hg19 for CTCF (ENCsR000EGM), NRF2 (ENCsR290MUH), NFE2 (ENCsR552YGL), and BACH1 (ENCsR740NPG) were obtained from the ENCODE project (64). HAP1-derived DNase-Seq data (ENCsR620QNS) that are mapped to hg19 were obtained from the ENCODE project (64). K562-derived raw SUMO2/3 ChiP-Seq data (GSE66448) (31) were obtained from GEO. The SUMO2/3 ChiP-Seq sequencing files were processed the same way as the ATAC-Seq files, where peak calling was made using MACS2 with the parameters “-m 5 50 -bw 500 -fix-bimodal -extsize 200 call summits -B -q 0.01”. Peak refinement was performed, and the resulting peak calls were used to generate heatmaps and profile (line) plots compared with the ATAC-Seq data.

**Author contributions**—F. R.-C., R. B. L., I. C., M. B., L. M. M., M. L., and O. S. G. investigation; F. R.-C., R. B. L., and R. E. methodology; F. R.-C., R. B. L., and R. E. writing-review and editing; R. B. L. data curation; R. B. L. formal analysis; R. E. resources; R. E. and O. S. G. supervision; R. E. and O. S. G. funding acquisition; O. S. G. conceptualization; O. S. G. writing-original draft; O. S. G. project administration.

**Acknowledgments**—We thank E. T. Yeh for the SENP1 cDNA-expressing plasmid and Keith Gull for the TY1 hybridoma cell line (BB2). We thank Bettina Maria Fuglerud for helpful discussions and guidance on the ATAC experiments. We also thank Vilborg Matre for co-supervising L. M. M. during screening and data analysis. The sequencing service was provided by the Norwegian Sequencing Centre, a national technology platform hosted by the University of Oslo and supported by the “Functional Genomics” and “Infrastructure” programs of the Research Council of Norway and the South-Eastern Regional Health Authorities. All genome-wide analyses were made on the Abel computer cluster (Project mn9374k), which is owned by the University of Oslo and the Norwegian metacentre for high-performance computing (NOTUR). The Abel Cluster is operated by the Department for Research Computing at USIT and the University of Oslo IT-department. We thank Arvind Sundaram for guidance on RNA-Seq analysis.

**References**

1. Gareau, J. R., and Lima, C. D. (2010) The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 11, 861–871 CrossRef Medline
2. Floto, A., and Melchior, F. (2013) SUMoylation: a regulatory protein modification in health and disease. Annu. Rev. Biochem. 82, 357–385 CrossRef Medline
3. Geiss-Friedlander, R., and Melchior, F. (2007) Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 8, 947–956 CrossRef Medline
4. Seeler, J.-S., and Dejean, A. (2003) Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell Biol. 4, 690–699 CrossRef Medline
5. Hendriks, I. A., Lyon, D., Young, C., Jensen, L. J., Vertegaal, A. C., and Nielsen, M. L. (2017) Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. Nat. Struct. Mol. Biol. 10.1038/nsmb.3366
6. Cumberas-Potts, C., and Matunis, M. I. (2013) SUMO: a multifaceted modifier of chromatin structure and function. Dev. Cell 24, 1–12 CrossRef Medline
7. Gill, G. (2003) Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Curr. Opin. Genet. Dev. 13, 108–113 CrossRef Medline
8. Nüñer-O’Marra, A., and Berra, E. (2013) Deciphering the emerging role of SUMO conjugation in the hypoxia-signaling cascade. *Biochim. Biophys. Acta* 1836, 459–469 CrossRef Medline
9. Chymkowski, P., Nguéa, P. A., Enserink, J. M. (2015) SUMO-regulated transcription: challenging the dogma. *Bioessays* 37, 1095–1105 CrossRef Medline
10. Kerscher, O. (2007) SUMO function—what’s your function? New insights through SUMO-interacting motifs. *EMBO Rep.* 8, 550–555 CrossRef Medline
11. Yeh, E. T. (2009) SUMOylation and De-SUMOylation: wrestling with life’s processes. *J. Biol. Chem.* 284, 8223–8227 CrossRef Medline
12. Hickey, C. M., Wilson, N. R., and Hochstrasser, M. (2012) Function and regulation of SUMO proteases. *Nat. Rev. Mol. Cell Biol.* 13, 755–766 CrossRef Medline
13. Huang, C.-J., Wu, D., Khan, F. A., and Huang, C.-J., Wu, D., Khan, F. A., and Huo, L.-J. (2015) DeSUMOylation: a therapeutic target and protein regulatory event. *DNA Cell Biol.* 34, 652–660 CrossRef Medline
14. Nacereddine, K., Lehembre, F., Bhamik, M., Artus, J., Cohen-Tannoudji, M., Babinet, C., Pandolfi, P. P., and Dejean, A. (2005) The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. *Dev. Cell* 9, 769–779 CrossRef Medline
15. Cheng, J., Kang, X., Zhang, S., and Yeh, E. T. (2007) SUMO-specific protease 1 is essential for stabilization of HIF1α in hypoxia. *Cell* 131, 584–595 CrossRef Medline
16. Kang, X., Qi, Y., Zuo, Y., Wang, Q., Zou, Y., Schwartz, R. J., Cheng, J., and Yeh, E. T. (2010) SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. *Mol. Cell* 38, 191–201 CrossRef Medline
17. Bartek, J., and Hodny, Z. (2010) SUMO boosts the DNA damage response barrier against cancer. *Cancer Cell* 17, 9–11 CrossRef Medline
18. Bettermann, K., Benesch, M., Weis, S., and Haybaeck, J. (2012) SUMOylation in carcinogenesis. *Cancer Lett.* 316, 113–125 CrossRef Medline
19. Sarge, K. D., and Park-Sarge, O.-K. (2011) SUMO and its role in human life’s processes. *Trends Biochem. Sci.* 36, 440–444 CrossRef Medline
20. Van Nguyen, T., Angkasekwinai, P., Dou, H., Lin, F.-M., Lu, L.-S., Cheng, J., Chiu, Y. E., Dong, C., and Yeh, E. T. (2012) SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. *Mol. Cell* 45, 210–221 CrossRef Medline
21. Hay, R. T. (2007) SUMO-specific proteases: a twist in the tail. *Trends Cell Biol.* 17, 370–376 CrossRef Medline
22. Mukhopadhyay, D., and Dasso, M. (2007) Modification in reverse: the SUMO pathway. *Cell* 131, 1135–1140 CrossRef Medline
23. Goodarzi, A. A., Kurta, T., and Jeggo, P. A. (2011) KAP-1 phosphorylation regulates CHD3 nucleosome remodeling during the DNA double-strand break response. *Nat. Struct. Mol. Biol.* 18, 831–839 CrossRef Medline
24. Carette, J. E., Raaben, M., Wong, A. C., Herbert, A. S., Obernosterer, G., Mulherkar, N., Kuehne, A. I., Kranzusch, P. J., Griffin, A. M., Ruthel, G., Dal Cin, P., Dye, J. M., Whelan, S. P., Chandran, K., and Brummelkamp, T. R. (2011) Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. *Nature* 477, 340–343 CrossRef Medline
25. Ouyang, J., and Gill, G. (2009) SUMO engages multiple corepressors to mediate polycomb group protein-mediated gene silencing during embryonic development. *Mol. Cell* 38, 191–201 CrossRef Medline
26. Stielow, B., Sapetschnig, A., Wink, C., Krüger, I., and Suske, G. (2008) Identification of SUMO-dependent chromatin-associating transcriptional repression components by a genome-wide RNAi screen. *Mol. Cell* 29, 742–754 CrossRef Medline
27. Lai, A. Y., and Wade, P. A. (2011) Cancer biology and NuRD: a multifaceted chromatin remodeling complex. *Nat. Review. Cancer* 11, 588–596 CrossRef Medline
28. Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., and Glass, C. K. (2010) Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* 38, 576–589 CrossRef Medline
29. Niskanen, E. A., Malinen, M., Sutinen, P., Toropainen, S., Paakimäki, V., Vihervaa, A., Joutsen, J., Kaikkonen, M. U., Sistolinen, L., and Palvimo, J. J. (2015) Global SUMOylation on active chromatin is an acute heat stress response restricting transcription. *Genome Biol.* 16, 153 CrossRef Medline
30. MacPherson, M. J., Beatty, L. G., Zhou, W., Du, M., and Sadowski, P. D. (2017) The chromatin remodelers CHD1 and CHD2 have opposing roles in T-cell development. *Nature* 547, 459–469 CrossRef Medline
**SENP1–CHD3 interaction and cooperation**

48. Whalen, S., Truty, R. M., and Pollard, K. S. (2016) Enhancer-promoter interactions are encoded by complex genomic signatures on looping chromatin. *Nat. Genet.* 48, 488–496 CrossRef Medline

49. Soufi, A., Garcia, M. F., Jaroszewicz, A., Osman, N., Pellegrini, M., and Zaret, K. S. (2015) Pioneer transcription factors target partial DNA motifs on nucleosomes to initiate reprogramming. *Cell* 161, 555–568 CrossRef Medline

50. Swinstead, E. E., Paakinaho, V., Presman, D. M., and Hager, G. L. (2016) Pioneer factors and ATP-dependent chromatin remodeling factors interact dynamically: a new perspective: multiple transcription factors can effect chromatin pioneer functions through dynamic interactions with ATP-dependent chromatin remodeling factors. *Bioessays* 38, 1150–1157 CrossRef Medline

51. Fuglerud, B. M., Lemma, R. B., Wanichawan, P., Sundaram, A. Y. M., Eskeland, R., and Gabrielsen, O. S. (2011) PIAS1 interacts with the chromatin remodeler Mi-2α as a novel co-activator for human c-Myb. *J. Biol. Chem.* 286, 13994–14005 CrossRef Medline

52. Saether, T., Berge, T., Ledsaak, M., Matre, V., Alm-Kristiansen, A. H., Saether, T., and Gabrielsen, O. S. (2011) PIAS1 interacts with c-Myb and modulates its activity through phosphorylation. *Nucleic Acids Res.* 45, 7681–7696 CrossRef Medline

53. Molværsmyr, A.-K., Saether, T., Gilfillan, S., Lorenzo, P. I., Kvaløy, H., Matre, V., and Gabrielsen, O. S. (2010) A SUMO-regulated activation function controls synergy of c-Myb through a repressor-activator switch leading to differential p300 recruitment. *Nucleic Acids Res.* 38, 4970–4984 CrossRef Medline

54. Bengtsen, M., Klepper, K., Gundersten, S., Cuervo, I., Drablos, F., Hovic, E., Sandve, G. K., Gabrielsen, O. S., and Eskeland, R. (2015) c-Myb binding sites in haematopoietic chromatin landscapes. *PLoS ONE* 10, e0133280 CrossRef Medline

55. Bastin, P., Bagherzadeh, Z., Matthews, K. R., and Gull, K. (1996) A novel epitope tag system to study protein targeting and organelle biogenesis in *Trypanosoma brucei*. *Mol. Biochem. Parasitol.* 77, 235–239 CrossRef Medline

56. Alm-Kristiansen, A. H., Saether, T., Gilfillan, S., Dahle, O., and Gabrielsen, O. S. (2008) FLASH acts as a co-activator of the transcription factor c-Myb and localizes to active RNA polymerase II foci. *Oncogene* 27, 4644–4656 CrossRef Medline

57. Matre, V., Nordgård, O., Alm-Kristiansen, A. H., Ledsaak, M., and Gabrielsen, O. S. (2009) HIPK1 interacts with c-Myb and modulates its activity through phosphorylation. *Biochem. Biophys. Res. Commun.* 388, 150–154 CrossRef Medline

58. Alm-Kristiansen, A. H., Lorenzo, P. I., Molværsmyr, A.-K., Matre, V., Ledsaak, M., Saether, T., and Gabrielsen, O. S. (2011) PIAS1 interacts with FLASH and enhances its co-activation of c-Myb. *Mol. Cancer* 10, 21 CrossRef Medline

59. Dahle Ø., Bakke, O., and Gabrielsen, O. S. (2004) c-Myb associates with PML in nuclear bodies in hematopoietic cells. *Exp. Cell Res.* 297, 118–126 CrossRef Medline

60. Wright, K. J., Marr, M. T., and Tjian, R. (2006) TAF4 nucleates a core subcomplex of TFIIID and mediates activated transcription from a TATA-less promoter. *Proc. Natl. Acad. Sci. U.S.A.* 103, 12347–12352 CrossRef Medline

61. Ledsaak, M., Bengtsen, M., Molværsmyr, A.-K., Fuglerud, B. M., Matre, V., Eskeland, R., and Gabrielsen, O. S. (2016) PIAS1 binds p300 and behaves as a coactivator or corepressor of the transcription factor c-Myb dependent on SUMO-status. *Biochim. Biophys. Acta* 1859, 705–718 CrossRef Medline

62. Buenrostro, J. D., Wu, B., Chang, H. Y., and Greenleaf, W. J. (2015) ATAC-seq: a method for assaying chromatin accessibility genome-wide. *Curr. Protoc. Mol. Biol.* 109, 21.29.1–9 CrossRef Medline

63. Buenrostro, J. D., Giurescu, P. G., Zaba, L. C., Chang, H. Y., and Greenleaf, W. J. (2013) Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nat. Methods* 10, 1213–1218 CrossRef Medline

64. ENCODE Project Consortium. (2012) An integrated encyclopedia of DNA elements in the human genome. *Nature* 489, 57–74 CrossRef Medline

65. Dahle Ø., Anderssen T. Ø., Nordgård, O., Matre, V., Del Sal, G., and Gabrielsen, O. S. (2003) Transactivation properties of c-Myb are critically dependent on two SUMO-1 acceptor sites that are conjugated in a PIASy enhanced manner. *Eur. J. Biochem.* 270, 1338–1348 CrossRef Medline

66. Alm-Kristiansen, A. H., Norman, I. L., Matre, V., and Gabrielsen, O. S. (2009) SUMO modification regulates the transcriptional activity of FLASH. *Biochem. Biophys. Res. Commun.* 387, 494–499 CrossRef Medline

67. Ramírez, F., Ryan, D. P., Grünbing, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., and Manke, T. (2016) deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res.* 44, W160–W165 CrossRef Medline

68. Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., and Haussler, D. (2002) The human genome browser at UCSC. *Genome Res.* 12, 996–1006 CrossRef Medline

69. Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., and Pachter, L. (2012) Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat. Protoc.* 7, 562–578 CrossRef Medline

70. Abegossisa, I., Shimoji, H., Sahin, S., Kondo, A., Harshbarger, J., Lizio, M., Hayashizaki, Y., Curninici, P., FANTOM consortium, Forrest, A., Kasukawa, T., and Kawaiji, H. (2016) FANTOM5 transcriptome catalog of cell states based on Semantic MediaWiki. *Database (Oxford)* 2016, baw105 CrossRef Medline